AGC Biologics Supports BioNTech Omicron-based Vaccine Candidate (Clone)
share
Excerpt
AGC Biologics announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility as a part to fight the pandemic variants.
Article Summary
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced partnership with Pfizer-BioNTech to provide more plasmid DNA (pDNA) starting material. Pfizer and BioNTech have announced that the companies have started to develop an Omicron-based COVID-19 vaccine with first batches expected to be ready for delivery by end of March 2022.
AGC Biologics Chief Executive Officer, Patricio Massera said, “We are proud to continue to support BioNTech and supply them with pDNA materials for their vaccine production, as a part of the fight against new pandemic variants.” He added, “Our pDNA services are a part of our growing global Cell and Gene Therapy offering that includes the development and manufacturing of cell therapies, viral vectors, and messenger RNA.”
With more than 20 years of experience delivering a wide range of programs for customers, the AGC Biologics Heidelberg facilityis the company’s Center of Excellence for pDNA production, and a central part of the AGC Biologics global network of cell and gene therapy-focused facilities.
About AGC Biologics
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), providing world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. AGC Biologics’ commitment to continuous innovation fosters the technical creativity to solve the customers’ most complex challenges, including specialization in fast track projects for orphan drugs and rare diseases.
(Source: AGC Biologics, 8th March 2022)
Comments
Leave A Comment
Leave a Reply
